


PRECLINICAL RESEARCH

# Cardiomyocyte Lineage Specification in Adult Human Cardiac Precursor Cells Via Modulation of Enhancer-Associated Long Noncoding RNA Expression



Isabelle Plaisance, PhD,<sup>a</sup> Stéphanie Perruchoud, MD,<sup>a</sup> Miguel Fernandez-Tenorio, PhD,<sup>b</sup> Christine Gonzales, PhD,<sup>a</sup> Samir Ounzain, PhD,<sup>a</sup> Patrick Ruchat, MD,<sup>c</sup> Mohamed Nemir, PhD,<sup>a</sup> Ernst Niggli, MD,<sup>b</sup> Thierry Pedrazzini, PhD<sup>a</sup>

## VISUAL ABSTRACT



## HIGHLIGHTS

- Human CPCs produce predominantly smooth muscle cells.
- CPCs can be redirected to the cardiomyocyte fate by transient activation followed by inhibition of NOTCH signaling.
- Inhibition of NOTCH signaling during differentiation represses *MIR-143/145* expression and blocks smooth muscle differentiation.
- Expression of the microRNAs is under control of *CARMEN*, a long noncoding RNA associated with an enhancer located in the *MIR-143/145* locus and target of NOTCH signaling.
- The *CARMEN/MIR-145/143* locus represents a promising therapeutic target to favor production of cardiomyocytes in cell replacement therapies.

From the <sup>a</sup>Experimental Cardiology Unit, Department of Medicine, University of Lausanne Medical School, Lausanne, Switzerland; <sup>b</sup>Department of Physiology, University of Bern, Bern, Switzerland; and the <sup>c</sup>Department of Cardiovascular Surgery, University of Lausanne Medical School, Lausanne, Switzerland. This project was supported in part by grants to Dr. Pedrazzini from the Swiss National Science Foundation, Bern, Switzerland (grants no 33CM30-124090 and no 406340-128129) and by the Novartis Foundation for Medical-Biological Research, Basel, Switzerland (grant no 15A048). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received April 28, 2016; revised manuscript received June 29, 2016, accepted June 30, 2016.

## SUMMARY

The mechanisms controlling differentiation in adult cardiac precursor cells (CPCs) are still largely unknown. In this study, CPCs isolated from the human heart were found to produce predominantly smooth muscle cells but could be redirected to the cardiomyocyte fate by transient activation followed by inhibition of NOTCH signaling. NOTCH inhibition repressed *MIR-143/145* expression, and blocked smooth muscle differentiation. Expression of the microRNAs is under control of *CARMEN*, a long noncoding RNA associated with an enhancer located in the *MIR-143/145* locus and target of NOTCH signaling. The *CARMEN/MIR-145/143* axis represents, therefore, a promising target to favor production of cardiomyocytes in cell replacement therapies. (J Am Coll Cardiol Basic Trans Science 2016;1:472-93) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The adult human heart has poor regenerative potential, and heart failure gradually develops following injury (1,2). Ultimately, heart transplantation represents the only therapeutic option for end-stage heart failure. Within this context, stimulation of cardiomyocyte production in the damaged heart to promote regeneration represents an attractive therapeutic approach (3,4). In particular, cell replacement therapy via injection of precursor cells into the damaged heart represents an interesting therapeutic avenue. The main challenge for transferring cell therapies for heart disease into a clinical setting is to identify a suitable source of human cardiac precursor cells (CPCs). Direct isolation of CPCs from the heart of cardiac patients would represent a great advantage by the autologous nature of the isolated cells. This would indeed reduce the problems associated with immune rejection. The existence of resident CPCs in the adult mammalian heart, including the human heart, capable of differentiating into functional cardiomyocytes, has been demonstrated (3,4). However, the number of CPCs in the adult myocardium is quite low, and isolation of these cells is a challenging procedure. Indeed, no truly specific markers are currently available to distinguish CPCs from other cell types (3,4). Multipotent mesenchymal stromal cells expressing cardiac transcription factors such as GATA4, NKX2.5, and MEF2C, but no proteins expressed by fully differentiated cardiomyocytes such as proteins of the sarcomere, could therefore be operationally defined as CPCs. Nevertheless, the effective generation of new cardiomyocytes from transferred CPCs is still a matter of intense debate, and restoration of function has been attributed to paracrine mechanisms mediated by factors secreted from the transferred cells (2-4). Therefore, a clear understanding of the regulatory networks controlling mobilization and differentiation of endogenous CPCs toward the cardiac lineage is

required in order to facilitate the ultimate goal of cardiac regeneration.

Several pathways that are important during cardiac morphogenesis are reactivated in the damaged myocardium. Among these, the NOTCH pathway plays crucial roles in the developing and adult heart (5,6). NOTCH is an evolutionarily conserved cell-to-cell communication system that takes place between 2 adjacent cells (7). The signal-sending cell expresses a membrane-bound ligand such as Jagged (J)1, J2, Delta-like1 (DLL1), DLL3, and DLL4, and the signal-receiving cell expresses a NOTCH receptor such as NOTCH (N)1, N2, N3, and N4. Receptor engagement results in its cleavage and liberation of the NOTCH intracellular domain (NICD). NICD translocates into the nucleus, where it interacts with co-activators, in particular a transcription factor known as RBPJ, to activate target gene expression. NOTCH target genes include repressors of the Hairy enhancer of split (*HES*) and the related *HEY* families (8). During development, NOTCH regulates trabeculation, myocyte proliferation, and valve formation. In the neonatal heart, NOTCH controls cardiac precursor expansion and differentiation (9). In the adult heart, NOTCH signaling is activated in cardiomyocytes, CPCs, and fibroblasts (10-14). Interestingly, NOTCH appears to prevent premature cardiogenic differentiation in precursor cells, and to favor proliferation in this transient amplifying cell compartment (14). Consistent with this observation, blockade of the NOTCH pathway in embryonic stem cells favors commitment into the cardiac mesoderm, and subsequently, into cardiomyocytes, at the expense of the neuroectodermal lineage (15). NOTCH signaling has also been reported to induce early cardiac commitment in embryonic and induced pluripotent stem cells, supporting a biphasic role of NOTCH in cardiogenesis (16). Accordingly, NOTCH signaling

## ABBREVIATION AND ACRONYMS

- CARMEN** = (CAR)dic (M)esoderm (E)nhancer-associated (N)oncoding RNA
- CPC** = cardiac precursor cell
- DLL1** = Delta-like1
- GO** = gene ontology
- J1** = Jagged1
- lncRNA** = long noncoding RNA
- miRNA** = microRNA
- NICD** = NOTCH intracellular domain
- RT-PCR** = reverse transcription polymerase chain reaction

was suggested to promote cardiogenesis in the post-natal heart (17,18). Furthermore, NOTCH has been implicated in the differentiation of cardiosphere-derived cells into smooth muscle cells (19). This finding is reminiscent of the role of NOTCH in vascular smooth muscle cells, in which Jagged1-activated NOTCH signaling promotes a differentiated phenotype (20). Interestingly, NICD, associated with RBPJ, binds to an enhancer within the locus encoding the small regulatory noncoding RNAs *MIR-143/145*, 2 microRNAs (*MIRs*) that were previously shown to regulate smooth muscle cell phenotype and behavior (20,21).

In recent years, it has become apparent that the noncoding genome is pervasively transcribed, generating thousands of long noncoding RNAs (lncRNAs). These transcripts, which are defined as being >200 nucleotides in length with no apparent protein coding potential, are typically expressed in a highly cell- and context-specific manner. lncRNAs are emerging, therefore, as master regulators of gene expression and important mediators of lineage-specific commitment during development (22,23). In the developing and adult hearts, lncRNAs are dynamically expressed and exert control of the cardiac gene regulatory network (24-26). A growing body of evidence suggests that they could be pivotal during the pathophysiological response in the damaged heart (27,28). lncRNAs efficiently operate in *cis*, at the site of transcription, and in *trans*, at remote locations in the genome. In particular, lncRNAs, which are transcribed from active enhancers, contribute to neighboring gene activation via *cis* mechanisms (29,30). In this context, we recently identified *CARMEN* [(CAR)diac (M)esoderm (E)nhancer-associated (N)oncoding RNA], a lncRNA that is a crucial regulator of cardiac specification in human CPCs isolated from the fetal heart (31,32). Interestingly, *CARMEN* is templated from the NOTCH-responsive enhancer element within the *MIR-143/145* locus. In the present study, we aimed at evaluating the cardiogenic potential of CPCs isolated from adult human hearts. We show that human clonogenic CPCs can be readily obtained from atrial appendages, expanded in vitro, and induced to differentiate into either smooth muscle cells or cardiomyocytes. This binary cell fate decision depends on the state of activation or inhibition of the NOTCH pathway. Activation of NOTCH signaling promotes adoption of a smooth muscle lineage, whereas sequential activation and inhibition favor cardiomyocyte specification. NOTCH signaling appears to target *CARMEN* in differentiating CPCs. More precisely, we demonstrated that a particular *CARMEN* isoform regulates commitment into the smooth muscle fate. Therefore, NOTCH inhibition, via

down-regulation of the smooth muscle cell-specific isoform of *CARMEN*, represses *MIR-143/145* expression, and forces CPCs to adopt a cardiomyocyte fate.

## METHODS

**CULTURE OF HUMAN ADULT CPCs.** Human atrial appendages were obtained from male patients (35 to 90 years old) undergoing cardiac surgery through donation. The protocol received authorization from the University Hospital Ethics Committee and the Cantonal Ethics Committee on research involving humans. Tissues were minced and enzymatically digested in a buffer containing 0.45 mg/ml collagenase (Worthington Biochemical Corporation, Lakewood, New Jersey) and 1 mg/ml pancreatin (Invitrogen, Carlsbad, California) (Supplemental Figure 1A). Following 24 hours in culture, cells that remained in suspension were discarded, and adherent cells were expanded in expansion medium (3:1 DMEM 1g/l glucose/Medium 199 [Invitrogen] supplemented with 10% horse serum [Serotec, Kidlington, United Kingdom], 5% fetal bovine serum [Serotec], 100 U/ml penicillin [Invitrogen], and 100 µg/ml streptomycin [Invitrogen]). For inducing differentiation, cells were switched to MEM alpha (Invitrogen) containing 2% horse serum, 1 µmol/l dexamethasone (Sigma-Aldrich, St. Louis, Missouri), 50 µg/ml ascorbic acid (Sigma-Aldrich), 10 mmol/l β-glycerophosphate (Sigma-Aldrich), 100 U/ml penicillin (Invitrogen), and 100 µg/ml streptomycin (Invitrogen) (differentiation medium [33]), and cultured for 2 to 3 weeks before analysis.

**EXPERIMENTS IN SCID NEONATES.** Immunodeficient SCID mice (S/B6.CB17-PrKdc scid Ma SN1913, The Jackson Laboratory, Bar Harbor, Maine) were used in cell transfer experiments. Animal experiments were approved by the Government Veterinary Office (Lausanne, Switzerland) and performed according to the guidelines from Directive 2010/63/EU of the European Parliament. Mice were maintained under specific pathogen-free conditions. CPCs were either not stimulated (None) or exposed to DLL1 for 24h. Cells ( $10^5$  in 50 µl NaCl 0.09%) were injected into neonatal mice through the superficial temporal vein. Twenty-four hours post cell-injection, the test group was injected with DAPT [N-(N-(3,5-difluorophenacetyl)-L-alanyl)S-phenylglycine t-butyl ester] diluted in dimethyl sulfoxide (DMSO) (4 µl/g of body weight/day), whereas the control group received DMSO only (No DAPT group) for 3 consecutive days. Twelve days post-injection, hearts were collected and embedded in optimal cutting temperature compound. To identify heart sections containing human cells, every second cryosection was collected for reverse transcription

polymerase chain reaction (RT-PCR) detection of the human  $\alpha$ -satellite chromosome (8 sections per PCR tube). Sections were digested with Proteinase K (Sigma-Aldrich) in Direct PCR Tail Buffer (Viagen Biotech, Los Angeles, California). DNA was amplified using Taq NEB (New England Biolabs, Ipswich, Massachusetts). The primers are described in the [Supplemental Methods](#). Immunostaining directed against human LAMIN and  $\alpha$ -ACTININ was performed. The surface of the LAMIN area was measured using confocal images and the ImageJ application (Version 1.50B, National Institutes of Health, Bethesda, Maryland). Tridimensional volumes were reconstructed using IMARIS software (Version 7.7.1, Bitplane, Belfast, United Kingdom).

**RNA SEQUENCING AND ANALYSIS.** Total RNA was isolated from proliferating and differentiated CPCs using the RNeasy isolation kit (Qiagen, Valencia, California). Sequencing libraries were prepared according to Illumina RNA Seq library kit instructions with Poly(A) selection (Illumina, San Diego, California). Libraries were sequenced with the Illumina HiSeq2000 (2 × 100 bp).

**STATISTICAL ANALYSIS.** All data were collected from at least 3 independent experiments, performed in triplicate. Data throughout the paper are expressed as mean ± SEM. Data were processed using GraphPad Prism (version 7.00, GraphPad Software, La Jolla, California), and analyzed by the Kolmogorov-Smirnov test to check for normal distribution. Analysis was performed using analysis of variance with post hoc Tukey test. For non-normally distributed data, Kruskal-Wallis analysis with the Dunn multiple comparison test were used, and median values were calculated. Values of  $p < 0.05$  were considered significant.

For transcriptomic data, statistical analysis was performed in R version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria). Raw counts were normalized using TMM (EdgeR, R version 3.4.0 [34]) for genes with 1 count per million (cpm) in at least 1 sample. Log transformation was applied on the normalized counts using Voom function (limma package, R version 3.18.2 [35]). Differential expression was computed with limma [36], and a moderated  $t$  test was used for each comparison. Adjusted  $p$  values were computed by the Benjamini-Hochberg method, controlling for a false discovery rate.

An expanded methods section is also available in the [Supplemental Appendix](#).

## RESULTS


### CHARACTERIZATION OF CARDIAC PRECURSOR CELLS ISOLATED FROM ADULT HUMAN ATRIAL APPENDAGES.

Human CPCs were isolated from right

atrial appendages of male patients (35 to 86 years old) undergoing cardiac surgery ([Supplemental Figure 1A](#)). Following expansion in vitro, we routinely obtained several 100 thousand cells from each biopsy ([Supplemental Table 1](#)). Cells could be stored frozen, thawed, and retained a proliferative capacity for more than 15 passages. We first measured the expression of markers of cardiac specification and differentiation by RT-PCR ([Figure 1A](#)). Under expansion conditions, these cells expressed early cardiac markers such as *GATA4*, *NKX2.5*, and *MEF2C*, but no markers of differentiated cardiomyocytes such as  $\alpha$ -myosin heavy chain (*MYH6*),  $\beta$ -myosin heavy chain (*MYH7*), cardiac actin (*ACTA*), or cardiac troponin I (*TNNI*). We examined cell surface marker expression by flow cytometry ([Figure 1B](#)). The cells uniformly expressed mesenchymal stem cell markers such as CD73, CD90, and CD105, whereas endothelial and hematopoietic markers (CD31, CD34, CD45), CD117 (KIT), CXCR4, and CD140 (PDGFR $\alpha$ ) were not expressed. A significant proportion expressed CD146, suggesting that they could derive from pericytes [37]. However, these cells did not express NG2, another pericyte marker. The characteristics of the isolated cells were further investigated by immunostaining. All cells were found positive for NKX2.5 ([Figure 1C](#)). In addition, NKX2.5-positive (NKX2.5<sup>POS</sup>) cells were MEF2C<sup>POS</sup>. The vast majority of NKX2.5<sup>POS</sup> cells (73%) also expressed GATA4. Proliferation was examined using immunostaining directed against the proliferation markers Ki67 and phospho-Histone 3 (PH3). Respectively, 37% and 24% of NKX2.5<sup>POS</sup> were found Ki67<sup>POS</sup> and pH3<sup>POS</sup>. Altogether, these data indicated that the isolated population was composed of proliferative CPCs from mesenchymal origin, which are referred throughout this paper as adult CPCs. Interestingly, adult CPCs exhibited similar characteristics as CPCs previously isolated from the human fetal heart, which were shown to produce fully differentiated cardiomyocytes [31].

### HUMAN ADULT CPCs DIFFERENTIATE PRIMARILY INTO SMOOTH MUSCLE CELLS.

To examine the potential of adult CPCs for producing a differentiated progeny, cells were exposed to a differentiation medium shown to induce robust cardiomyocyte differentiation in human fetal CPCs [31,33]. Under these conditions, however, adult CPCs produce exclusively smooth muscle cells ([Supplemental Figures 1B and 1C](#)). Three weeks after inducing differentiation, expression of smooth muscle myosin heavy chain (*MYH11*) was significantly increased. In addition, 80% of the cells were smooth muscle-myosin heavy chain (SM-MHC)<sup>POS</sup> by immunostaining, whereas <1% stained positive for the cardiomyocyte-specific

**FIGURE 1** Characterization and Differentiation of Adult CPCs

**(A)** Expression of early (*GATA4*, *MEF2C*, *NKX2.5*) and late cardiac markers (*MYH6*, *MYH7*, *TNNI*, *CX43*) in the human adult heart and in isolated cardiac precursor cells (CPCs). **(B)** Flow cytometry analysis of CD31, CD34, CD45, CD73, CD90, CD105, CD117, CXCR4, CD140a, CD146, and NG2 expression in adult CPCs. Histograms show control (gray) and specific fluorescent intensity signal (white). **(C)** Analysis of cardiac transcription factor and proliferation marker expression by immunostaining. Nuclei were stained with DAPI (blue). Scale bar: 20  $\mu$ m. Quantification of NKX2.5<sup>POS</sup>/GATA4<sup>POS</sup>, NKX2.5<sup>POS</sup>/MEF2C<sup>POS</sup>, NKX2.5<sup>POS</sup>/PH3<sup>POS</sup>, and NKX2.5<sup>POS</sup>/KI67<sup>POS</sup> CPCs. Data represent mean  $\pm$  SEM (minimum 4,000 cells in 50 different fields at a magnification of 40 $\times$  per quantification). **(D)** Gene expression of *MYH6*, *MYH7*, *TNNI*, *ACTA*, and *MYH11* in proliferating CPCs (Expansion; black) and in adult CPCs exposed to DLL1 (gray), and differentiated in the absence (upper panels) or presence of DAPT (lower panels). Data represent mean  $\pm$  SEM; \**p* < 0.05 as compared with proliferating CPCs; #*p* < 0.05 as compared with differentiating unstimulated (None; white) CPCs in absence of DAPT (*n* = 5). **(E)** Analysis of SM-MHC and  $\alpha$ -ACTININ expression by immunostaining in CPCs exposed or not to DLL1 and differentiated in the absence or presence of DAPT. Nuclei were stained with DAPI (blue). Scale bars: 20  $\mu$ m. **(F)** Quantification of SM-MHC<sup>POS</sup> and  $\alpha$ -ACTININ<sup>POS</sup> in adult CPCs exposed to DLL1 (gray), and differentiated in the absence or presence of DAPT. Data represent mean  $\pm$  SEM; \**p* < 0.05 as compared with proliferating CPCs; #*p* < 0.05 as compared with differentiating unstimulated (None) (white) CPCs in absence of DAPT (minimum 2,000 cells in 30 different fields at a magnification of 40 $\times$  per quantification). Diff = differentiation medium; Exp = expansion medium.



marker  $\alpha$ -ACTININ. Cardiac transcription factors (*GATA4*, *MEF2C*, *NKX2.5*) and differentiation markers (*MYH6* and *MYH7*) were minimally induced. No endothelial cells were detected in differentiating cell cultures (data not shown). Therefore, adult CPCs displayed limited cardiogenic potential under these conditions, and differed markedly from fetal CPCs in their capacity to produce cardiomyocytes (31). In order to investigate the underlying mechanisms controlling adult CPC differentiation, we first compared expression of various cardiac markers in adult vs. fetal CPCs under basal and differentiation conditions. Cardiac transcription factors (*GATA4*, *MEF2C*, *NKX2.5*, and *TBX5*) were significantly more expressed in fetal than in adult CPCs, suggesting that fetal CPCs are more committed to the cardiac lineage than adult CPCs (Supplemental Figure 1D). Furthermore, *MYH6* and *MYH7* were significantly induced in fetal CPCs upon differentiation, whereas these genes were not activated in adult CPCs (Supplemental Figure 1E). On the contrary, *MYH11* expression was induced in adult CPCs during the differentiation process.

**NOTCH ACTIVATION STIMULATES CARDIAC TRANSCRIPTION FACTOR EXPRESSION AND PROLIFERATION IN ADULT CPCs.** Because of the role of the NOTCH pathway in cardiac precursor renewal and differentiation during development and in the adult heart, we measured expression of NOTCH receptors and ligands in fetal and adult CPCs (Supplemental Figure 2A). Although expression of all NOTCH receptors was comparable between fetal and adult CPCs, NOTCH ligands, i.e., *J1*, *J2*, *DLL1*, *DLL3*, and *DLL4* were significantly down-regulated in adult CPCs. The levels of *HES1* and *HEY1* were also significantly lower in adult CPCs, whereas *HEY2* was more expressed. These results led us to postulate that activation of NOTCH signaling could contribute to sustaining cardiogenesis in fetal CPCs. Therefore, we investigated the possibility of restoring a cardiogenic potential in adult CPCs via manipulation of the NOTCH pathway. Adult CPCs were cultured on immobilized DLL1 ligand to activate NOTCH signaling (Supplemental Figure 2B). The efficiency of this procedure was demonstrated using the hN1 reporter cell line, in which YFP expression is driven by N1ICD/RBPJ (Supplemental Figure 2C) (38). Activation of NOTCH signaling in adult CPCs exposed to immobilized DLL1 was verified by the induction of *HES1*, *HEY1*, and *HEY2* transcription (Supplemental Figure 2D). This manipulation had no significant effect on expression of NOTCH receptors and ligands. Exposure to DLL1 markedly stimulated proliferation in adult CPCs as judged by expression of several

genes encoding positive (*CCND1*, *C-MYC*, and *PCNA*) and negative (*CDK1A*) regulators of the cell cycle (Supplemental Figure 2E). Consistently, EdU (5-ethynyl-2'-deoxyuridine) incorporation was also higher in NOTCH-induced CPCs (Supplemental Figure 2F). We next evaluated the impact of NOTCH stimulation in adult CPCs on the expression of cardiac transcription factors. DLL1-mediated NOTCH activation induced a marked expression of *GATA4*, *NKX2.5*, *MEF2C*, and *TBX5* (Supplemental Figures 2G and 2H). Importantly, exposure to DLL1 increased the number of *NKX2.5*<sup>POS</sup>, *GATA4*<sup>POS</sup>, *MEF2C*<sup>POS</sup> CPCs (Supplemental Figure 2I).

**SEQUENTIAL NOTCH ACTIVATION AND INHIBITION IN ADULT CPCs FAVORS DIFFERENTIATION INTO CARDIOMYOCYTES.**

To investigate whether the increase in cardiac transcription factor expression following NOTCH activation restored a cardiogenic potential in adult CPCs, DLL1-stimulated CPCs were cultured under differentiation conditions. However, NOTCH-stimulated CPCs produced again exclusively smooth muscle cells (Figures 1D [upper panel] to 1F). Indeed, these cells demonstrated high *MYH11* expression and no expression of cardiomyocyte markers such as *MYH6* and *MYH7*. As a consequence, the vast majority of differentiated cells were SM-MHC<sup>POS</sup>, whereas none expressed  $\alpha$ -ACTININ. The action of NOTCH as an inducer of cardiac commitment and proliferation is in accordance with previous observations in CPCs and immature cardiomyocytes (10,14,39,40). However, NOTCH also exerts inhibitory actions on terminal cardiac differentiation (10,15,40). Therefore, while promoting CPC specification, NOTCH could at the same time block cardiomyocyte production from committed CPCs. To examine this possibility, adult CPCs were exposed to DLL1 and induced to differentiate in the presence of DAPT, an inhibitor of gamma secretase and thereby of the NOTCH pathway (Supplemental Figure 3A). DAPT efficiently blocked NOTCH signaling during differentiation as judged by the blunted expression of NOTCH target genes in treated CPCs (Supplemental Figure 3B). In sharp contrast to what was observed in the absence of DAPT, a marked expression of cardiac transcription factors and genes expressed in terminally differentiated cardiomyocytes were readily observed in NOTCH-inhibited CPCs, which therefore produced  $\alpha$ -ACTININ<sup>POS</sup> cardiomyocytes and very few smooth muscle cells (Supplemental Figure 3C, Figures 1D to 1F). Importantly, exposure to DLL1 was a prerequisite for restoring the cardiogenic potential in differentiating CPCs. Indeed, in the absence of this sensitization step, adult CPCs gave


rise to smooth muscle cells even if treated with DAPT. These results underlined the importance of a transient NOTCH activation to promote cardiomyocyte specification. Moreover, we formally demonstrated the dependence on the NOTCH1 signaling pathway for specifying CPCs in the cardiomyocyte lineage by taking advantage of selective inhibitory antibodies directed against N1 (namely NRR1 [41]). Specific blockade of NOTCH1-mediated pathways in differentiating DLL1-sensitized CPCs was sufficient for producing cardiomyocytes (Supplemental Figure 3D). These experiments rule out nonspecific effects of DAPT in differentiating CPCs. Finally, it is important to note that CPCs exposed to a different NOTCH ligand, i.e., J1, were equally able to produce cardiomyocytes following NOTCH inhibition (Supplemental Figure 4). However, J1-activated CPCs did not demonstrate increased proliferation. Therefore, DLL1 was chosen for further experiments.

**ADULT CPC-DERIVED CARDIOMYOCYTES EXHIBIT FUNCTIONAL ELECTRICAL PROPERTIES.** To functionally characterize CPC-derived cardiomyocytes, we first measured expression of several calcium handling proteins (Figure 2A). Expression of the L-type calcium channel (*CAV1.2*), ryanodine receptor (*RYR2*), and sarcoplasmic reticulum calcium ATPase (*SERCA2B*) was induced in adult CPCs differentiating into cardiomyocytes. Marginal expression was observed in situations giving rise to smooth muscle cells. To evaluate whether differentiating CPCs exhibited electrophysiological properties, we assessed  $Ca^{2+}$  signaling in resting and field-stimulated cells (Figure 2B). Under resting conditions or pacing (0.5 Hz), undifferentiated proliferating CPCs did not exhibit any calcium transients. Similarly, the 2 groups of differentiated cells did not show significant spontaneous calcium response. By contrast, electrical pacing triggered a marked and synchronized increase in cytosolic  $Ca^{2+}$  in CPC-derived cardiomyocytes produced by exposure to DLL1 and the presence of DAPT during differentiation. These findings were consistent with cardiomyocytes exhibiting functional calcium-induced calcium release when electrically stimulated. These calcium signals appear to last longer than those present in fully differentiated cardiomyocytes, similar to observations made in differentiating induced pluripotent stem cells (42). Although some calcium transients were detected in CPC-derived smooth muscle cells, the 2 differentiating populations differed markedly in their capacity to respond to electrical stimulation (Videos 1 and 2). Quantification of the response, as measured by determining the number of responding cells,

amplitude of the calcium transients, and time to reach maximal  $Ca^{2+}$  release, supported electrical competence in CPC-derived cardiomyocytes as compared with smooth muscle cells (Figure 2C). These data demonstrated that the CPC-derived cardiomyocytes developed electrical properties similar to those of mature cardiomyocytes.

**ADULT HUMAN CPCs PRODUCE CARDIOMYOCYTES IN VIVO.** To determine whether adult CPCs could produce cardiomyocytes in vivo, cells were injected into SCID mouse neonates intravenously. This protocol was previously demonstrated to result in significant engraftment and differentiation of CPCs in the post-natal heart (33). Cells were, therefore, either exposed or not to DLL1, and injected into neonatal mice, which then were administered with DAPT to favor cardiac differentiation (Supplemental Figure 5A). Twelve days thereafter, hearts were sectioned entirely and analyzed to determine the degree of CPC engraftment and differentiation. We first used PCR to detect human satellite DNA in cryosections. Provided that CPCs were exposed to DLL1, DAPT treatment promoted engraftment as shown by the increased number of PCR-positive sections in the relevant group (Supplemental Figure 5B). To further quantify engraftment and differentiation of human CPCs within the host myocardium, we performed immunostaining directed against human (h)LAMIN (human-specific antigen) and  $\alpha$ -ACTININ (cardiac marker). Occasional undifferentiated human CPCs were detected in the hearts of mice receiving no DAPT (Figure 2D). Similarly, in mice treated with DAPT but injected with CPCs that were not exposed to DLL1, hLAMIN<sup>POS</sup> cells did not differentiate into cardiomyocytes (Supplemental Figure 5C). Strikingly, in the group receiving DLL1-sensitized CPCs and treated with DAPT, large clusters of hLAMIN<sup>POS</sup> human cells expressing  $\alpha$ -ACTININ were readily detected (Figures 2D and 2E). Quantification of hLAMIN area confirmed that numerous human cells engrafted in the mouse myocardium under these conditions (Figure 2F). To ascertain the degree of differentiation of CPC-derived cardiomyocytes, we performed confocal microscopy. Z-stack analysis across hLAMIN<sup>POS</sup> human cardiomyocytes confirmed colocalization of hLAMIN and  $\alpha$ -ACTININ (Supplemental Figure 5D). Sarcomeric organization confirmed that transferred CPCs gave rise to mature cardiomyocytes. Finally, we generated a tridimensional reconstruction of areas containing human cardiomyocytes, which supported functional integration of human cardiomyocytes in the mouse myocardium (Figure 2G). Altogether, these data indicated that NOTCH

**FIGURE 2 Adult CPCs Produce Functional Cardiomyocytes In Vitro and In Vivo**



**(A)** Expression of calcium handling proteins (*CAV1.2*, *RYR2*, *SERCA2B*) in proliferating CPCs (Expansion; **black**) and in adult CPCs exposed to DLL1 (**gray**), and differentiated in the absence or presence of DAPT. Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs;  $\#p < 0.05$  as compared with differentiating unstimulated (None; **white**) CPCs in absence of DAPT ( $n = 4$ ). **(B)** Cytosolic  $Ca^{2+}$  signals were recorded in adult CPCs in expansion (**upper panels**), and in differentiating CPCs following exposure or not to DLL1 in the presence of DAPT. Cells were either evaluated under resting conditions or electrical stimulated (10 s at 0.5 Hz). Scale bar: 50  $\mu$ m. Representative tracing of normalized  $Ca^{2+}$  changes obtained following induction of pacing (**arrow**). **Colored lines** correspond to regions of recording as indicated in **B**. Images depicted in **B** were taken at the indicated time (\*). See **Videos 1** and **2**. **(C)** Quantification of calcium transient parameters. Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs;  $\#p < 0.05$  as compared with differentiating unstimulated (None) (**white**) CPCs in absence of DAPT ( $n = 55$  cells per quantification). **(D)** Analysis of h-LAMIN (**red**) and  $\alpha$ -ACTININ expression (**green**) in human CPC-derived cardiomyocytes in SCID mouse heart sections by immunostaining. DLL1-stimulated CPCs were injected in neonatal SCID mice. Mice were injected with DAPT or vehicle alone. Nuclei were stained with DAPI (**blue**). Scale bars: 20  $\mu$ m. **(E)** High magnification of human hLAMIN<sup>POS</sup>  $\alpha$ -ACTININ<sup>POS</sup> cardiomyocytes in the mouse myocardium. Scale bars: 20  $\mu$ m. **(F)** Quantification of human hLAMIN<sup>POS</sup> cardiomyocyte patches in SCID mouse hearts. Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with control group (unstimulated CPCs [None]; No DAPT administration);  $\#p < 0.05$  as compared with the group of animals injected with CPCs exposed to DLL1 (**gray**), but not injected with DAPT (minimum 3,000 cells in 40 different fields at a magnification of 40 $\times$  per quantification, 3 animals per condition). **(G)** Confocal analysis and tridimensional reconstruction of a representative patch of human cardiomyocytes in the mouse myocardium. **(a)** Confocal image of a representative patch. Scale bars: 20  $\mu$ m. **(b and c)** Tridimensional reconstruction of the representative human cardiomyocyte depicted in **a**. hLAMIN (**red**),  $\alpha$ -ACTININ expression (**green**), DAPI (**blue**). Scale bar: 5  $\mu$ m. **(d and e)** High magnifications of areas indicated in **b and c**. Scale bar: 20  $\mu$ m. Abbreviations as in **Figure 1**.



signaling could be modulated in vivo to enhance the specification of adult CPCs towards the cardiomyocyte fate.


**NOTCH-DEPENDENT *MIR-143/145* EXPRESSION CONTROLS DIFFERENTIATION OF ADULT CPCs INTO SMOOTH MUSCLE CELLS.** Proliferation and differentiation of smooth muscle cells has been shown to be regulated by *MIR-143/145* (20,21). We therefore measured *MIR-143/145* expression in fetal and adult CPCs (Supplemental Figure 6A). The expression levels of both microRNAs (miRNAs) were strongly down-regulated in fetal CPCs during spontaneous differentiation into cardiomyocytes. In sharp contrast, expression was markedly induced during differentiation of adult CPCs, consistent with their preferential commitment toward the smooth muscle cell lineage. We next evaluated whether *MIR-143/145* expression was modulated in adult CPCs according to their differentiation into either cardiomyocytes or smooth muscle cells. Adult CPCs were, therefore, induced to differentiate following exposure to DLL1 in the presence or absence of DAPT. *MIR-143/145* expression was measured under these different conditions (Figure 3A). Expression of *MIR-143/145* was robustly increased in all situations giving rise to smooth muscle cells. On the contrary, expression of the two miRNAs was significantly blunted in CPCs giving rise to cardiomyocytes. Target genes of *MIR-143/145*, negatively controlling smooth muscle cells differentiation, have been previously identified (21). Expression of ETS-domain protein 1 (*ELK1*) and Krueppel-like factor 4 (*KLF4*) was, therefore, measured. *ELK1* and *KLF4* were found to be up-regulated in adult CPCs differentiating into cardiomyocytes, concomitantly with *MIR-143/145* down-regulation (Figure 3A). These results demonstrated that *MIR-143/145* were under control by the NOTCH pathway in adult CPCs.

To further investigate the importance of *MIR-143/145* in lineage determination in adult CPCs, we used anti-MIR LNA inhibitors and miRNA mimics to modulate *MIR-143/145* activity during adult CPC differentiation. We first cultured CPCs under conditions that favor smooth muscle cell differentiation (i.e., no exposure to DLL1 and no DAPT) (Supplemental Figure 6B), and transfected these cells with anti-*MIR-143* and anti-*MIR-145* LNA inhibitors, alone or in combination (Figures 3B and 3C). Efficient MIR blockade was demonstrated by the reduced mature MIR levels observed in transfected adult CPCs and the up-regulation of the corresponding target genes in these cells. CPCs receiving no inhibitors or transfected with a scrambled LNA inhibitor produced smooth muscle cells, as judged by high *MYH11*


expression and low expression of *MYH6* and *MYH7* in differentiating cells. Furthermore, CPCs transfected with either the anti-*MIR-143* or the anti-*MIR-145* LNA demonstrated a reduced capacity to produce smooth muscle cells. These cells, however, did not give rise to cardiomyocytes. In sharp contrast, CPCs transfected with a combination of anti-*MIR-143* and anti-*MIR-145* were characterized by up-regulation of *MYH6* and *MYH7*, down-regulation of *MYH11*, and therefore, massively differentiate into cardiomyocytes (Figure 3D). We subsequently evaluated whether *MIR-143/145* expression were sufficient to force CPCs to differentiate into smooth muscle cells. For this, CPCs were exposed to DLL1 and cultured in the presence of DAPT, a protocol inducing cardiomyocyte production (Supplemental Figure 6C). Untransfected CPCs or CPCs transfected with a scrambled miRNA mimic demonstrated high *MYH6* and *MYH7*, and low *MYH11* expression, indicating that these cells differentiated into cardiomyocytes (Supplemental Figures 6D and 6E). On the contrary, when CPCs were transfected with either a *MIR-143* or a *MIR-145* mimic, *MIR-143/145* target genes were down-regulated, *MYH6* and *MYH7* expression was significantly blunted, and *MYH11* expression was markedly induced, showing that CPCs were redirected into the smooth muscle cell lineage. Altogether, these data indicated that *MIR-143* and *MIR-145* were indispensable for specifying adult CPCs into the smooth muscle fate. It further demonstrated that concomitant inhibition of the 2 miRNAs was sufficient to promote cardiogenesis in adult CPCs.

**BINARY CELL FATE DECISION BETWEEN THE CARDIOMYOCYTE AND SMOOTH MUSCLE CELL FATES IN ADULT CPC CLONES.** In order to demonstrate the potential of individual CPCs to adopt a cardiomyocyte and a smooth muscle cell fate, we derived a series of clones from proliferating adult CPCs. Figure 4 depicts results obtained with 1 clone, representative of 15 sharing a similar phenotype in 3 independent experiments. This clone expressed cardiac transcription factors and demonstrated a surface phenotype identical to that observed for the bulk population (Figures 4A and 4B). Although CD140a (PDGFR $\alpha$ ) and NG2 were not detected on the surface of the different clones, these populations expressed homogeneously CD146, confirming their probable pericyte origin. Furthermore, all clones were found positive for NKX2.5, GATA4, and MEF2C, and maintain a high proliferative capacity. Importantly, provided that they were subjected to DLL1 and DAPT during differentiation, the clones produced large amounts of cardiomyocytes (Figures 4D and 4E). Cardiomyocytes stained positive

**FIGURE 3 NOTCH-Mediated Regulation of Cell Fate Decision Between the Smooth Muscle Cell and Cardiomyocyte Lineages Depends on MIR-143/145 Expression**



**(A)** Expression of *MIR-143* and *MIR-145* in proliferating CPCs (Expansion; **black**) and in adult CPCs exposed to DLL1 (**gray**), and differentiated in the absence (**upper panels**) or presence of DAPT (**lower panels**). Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs;  $\#p < 0.05$  as compared with differentiating unstimulated (None; **white**) CPCs in absence of DAPT ( $n = 5$ ). **(B)** Expression of *MIR-143*, *-145*, and miRNA targets (*ELK1*, *KLF4*) in proliferating CPCs (Expansion; **black**) and in differentiated adult CPCs (without prior DLL1 exposure, in the absence of DAPT). Cells were either transfected (**white**) or not (None; **gray**) with the indicated miRNA LNA inhibitor. Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs;  $\#p < 0.05$  as compared with differentiating CPCs transfected with scrambled miRNA LNA inhibitor ( $n = 3$ ). **(C)** Expression of sarcomeric proteins (*MYH6*, *MYH7*, *MYH11*) in proliferating CPCs (Expansion; **black**) and in differentiated adult CPCs (without prior DLL1 exposure, in the absence of DAPT). Cells were transfected (**white**) or not (None; **gray**) with the indicated miRNA LNA inhibitor. Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs;  $\#p < 0.05$  as compared with differentiating CPCs transfected with scrambled miRNA LNA inhibitor (Scr) ( $n = 3$ ). **(D)** Analysis of SM-MHC and  $\alpha$ -ACTININ expression by immunostaining in differentiated CPCs (without prior DLL1 exposure, in the absence of DAPT), transfected or not with the indicated miRNA LNA inhibitor. Nuclei were stained with DAPI (**blue**). Scale bars: 50  $\mu$ m. Quantification of the numbers of  $\alpha$ -ACTININ<sup>POS</sup> cardiomyocytes or sm-MHC<sup>POS</sup> smooth muscle cells. Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs;  $\#p < 0.05$  as compared with differentiating CPCs transfected with scrambled miRNA LNA inhibitor (Scr) (minimum 2,000 cells in 30 different fields at a magnification of 40 $\times$  per quantification). Abbreviations as in **Figure 1**.

**FIGURE 4** Analysis of Representative Human CPC Clones

**(A)** Flow cytometric analysis of CD31, CD34, CD45, CD73, CD90, CD105, CD117, CXCR4, CD140a, CD146, and NG2 expression in 1 CPC clone. Histograms show control (gray) and specific fluorescent intensity signal (white). **(B)** Analysis of cardiac transcription factor expression by immunostaining. NKX2.5 (red); MEF2C (green). Nuclei were stained with DAPI (blue). **(C)** Expression of cardiac transcription factors (*GATA4*, *MEF2C*, *NKX2.5*), and sarcomeric proteins (*MYH6*, *MYH7*, *MYH11*) in proliferating adult CPCs (Expansion; black) and in adult CPCs exposed to DLL1 (gray), and differentiated in the absence (upper panels) or presence of DAPT (lower panels). Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs; † $p < 0.05$  as compared with differentiating unstimulated (None; white) CPCs in absence of DAPT ( $n = 3$ ). **(D)** Analysis of SM-MHC and  $\alpha$ -ACTININ expression by immunostaining in CPCs exposed or not to DLL1 and differentiated in the absence or presence of DAPT. Nuclei were stained with DAPI (blue). Scale bars: 20  $\mu$ m. **(E)** Analysis of  $\alpha$ -ACTININ (green) and TNNI (magenta), or MLC2V (magenta) expression by immunostaining in CPCs-derived cardiomyocytes. Nuclei were stained with DAPI (blue). Scale bars: 20  $\mu$ m. **(F)** Cytosolic  $Ca^{2+}$  were recorded in CPCs-derived cardiomyocytes. Cells were either evaluated under resting conditions, electrical stimulation (30 V, 2 ms at 5 Hz), or perfusion with caffeine. Spontaneous (top panel) and evoked (middle panel)  $Ca^{2+}$  oscillations were detected. Quantification shows the percentage of cells with spontaneous  $Ca^{2+}$  activity or responding to caffeine. Abbreviations as in Figure 1.

for  $\alpha$ -ACTININ, troponin I (TNNI), and myosin light chain 2v (MLC2V), showing their relative mature phenotype. Furthermore, spontaneous and evoked calcium transients demonstrated electrical competence (Figure 4F). The differentiated cells also responded to caffeine, suggesting that calcium-induced calcium release operated normally. In the absence of this sequential NOTCH activation and inhibition, these clones produced exclusively smooth muscle cells. These results demonstrated the bipotential of single adult CPCs to differentiate into either smooth muscle cells or cardiomyocytes.


**CARMEN, AN ENHANCER-ASSOCIATED lncRNA, CONTROLS MIR-143/145 EXPRESSION AND THE SMOOTH MUSCLE CELL FATE IN ADULT CPCs.** Using transcriptome profiling to identify lncRNAs that were differentially expressed in human fetal CPCs during differentiation into cardiomyocytes, we recently discovered *CARMEN*, an enhancer-associated lncRNA (32). Importantly, *CARMEN* is located in the genome immediately upstream of *MIR-143/145*, and corresponds to the enhancer that has been shown to be the target of NOTCH signaling in smooth muscle cells (20,32). We therefore investigated whether *CARMEN* was implicated in lineage determination in adult CPCs. Ten different *CARMEN* isoforms have been identified. We thus named these isoforms *CARMEN1* to *10* (Figure 5A). Primers were designed to measure individual expression of *CARMEN1*, 2, 3, 6, 7, 8, 9, and *10*. Specifically, we measured the expression of each isoform in differentiating fetal CPCs that gave rise to cardiomyocytes, and in adult clonal CPCs differentiating into either smooth muscle cells or cardiomyocytes (Figure 5B). In adult CPCs differentiating into smooth muscle cells, all *CARMEN* isoforms were either up-regulated or not modulated. By contrast, in fetal CPCs, a single isoform, *CARMEN7*, was significantly down-regulated during differentiation into cardiomyocytes. In addition, expression of all isoforms including *CARMEN7* was abolished in adult CPCs subjected to sequential NOTCH activation and inhibition to promote a cardiomyocyte fate. In order to determine whether *CARMEN7* and *MIR-143/145* were indeed coregulated in adult CPCs, we measured their expression in different situations favoring the emergence of a smooth muscle cell or a cardiomyocyte lineage (Figure 5C). In adult CPCs producing smooth muscle cells, *CARMEN7* and *MIR-143/145* were highly expressed. As a consequence, *KLF4* and *ELK1* expression was minimal. By contrast, *CARMEN7* and *MIR-143/145* were down-regulated in adult CPCs specified into the cardiomyocyte fate.

In this case, the levels of *KLF4* and *ELK1* were elevated.

**TARGETING CARMEN7 INHIBITS SMOOTH MUSCLE COMMITMENT AND PROMOTES A CARDIOMYOCYTE FATE IN ADULT CPCs.**

Since a positive correlation existed between *CARMEN7* and *MIR-143/145* expression, we postulated that *CARMEN7* could directly control *MIR-143/145* expression via *cis*-acting regulation, a mechanism that is common for enhancer-derived lncRNAs (30,43). To test this hypothesis, we designed modified antisense oligonucleotides (GapmeRs) targeting either all *CARMEN* isoforms or specifically *CARMEN7*, that is, in the latter case, the unique exon that is specific of this particular isoform. Adult CPCs were induced to differentiate into smooth muscle cells (no *DLL1* exposure, no *DAPT*), a situation in which all *CARMEN* isoforms are significantly expressed. Cells were in addition transfected with GapmeRs directed against either all *CARMEN* isoforms or uniquely *CARMEN7*. The experiment demonstrated that *CARMEN7* was the only isoform specifically down-regulated by *CARMEN7* GapmeRs, whereas the pan-*CARMEN* GapmeRs abolished expression of all isoforms (Supplemental Figure 7A). We next used these 2 different GapmeRs to evaluate the significance of *CARMEN7* in the regulation of the smooth muscle cell versus cardiomyocyte fate in differentiating adult CPCs. We first evaluated the effects of *CARMEN7* blockade on expression of *MIR-143/145* and their respective target genes. Specific *CARMEN7* knockdown resulted in a marked down-regulation of *MIR-143/145* expression, and a simultaneous up-regulation of *ELK1* and *KLF4* expression (Figure 6A).


The role of *CARMEN7* in the adoption of a particular fate was then investigated in adult CPCs. CPC clones were therefore cultured under differentiating conditions after no or previous exposure to *DLL1*, and in the absence or presence of *DAPT* (Supplemental Figure 7B). Cells were transfected with either control scrambled GapmeRs, GapmeRs targeting all *CARMEN* isoforms or *CARMEN7*-specific GapmeRs. Specification into the smooth muscle fate was completely blocked by GapmeRs directed against either all *CARMEN* isoforms or *CARMEN7*, as judged in particular by the down-regulation of *MYH11* expression and the marked decrease in the number of SM-MHC<sup>POS</sup> cells in all experimental conditions (Figures 6B and 6C). These findings confirmed the dependence of the smooth muscle lineage on *CARMEN7* expression. The 2 GapmeRs alone did not, however, impact significantly cardiogenesis. Indeed, in transfected CPCs that were not exposed to

**FIGURE 5** *CARMEN* Transcripts Are Differentially Regulated During Fetal and Adult Differentiation Into Smooth-Muscle Cells Or Cardiomyocytes

**(A)** UCSC screenshot of the human *CARMEN* locus. The 10 *CARMEN* isoforms, that is, *CARMEN1*, 2, and 3, 4, 5, 6, 7, 8, 9, and 10 are indicated in red. The 2 miRNAs, *MIR-143/145*, are indicated in green. **(B)** Expression of *CARMEN* transcripts (*CARMEN1*, 2, 3, 6, 7, 8, 9, 10) in proliferating (Expansion; white), and in differentiated fetal and adult CPCs without prior DLL1 stimulation and cultured in the absence of DAPT (Differentiation; black) or after stimulation with DLL1 and cultured in presence of DAPT (DLL1/DAPT/Differentiation; light gray). Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs ( $n = 4$ ). **(C)** Expression of *CARMEN7*, *MIR-143*, *MIR-145*, *ELK1*, and *KLF4* transcripts in proliferating CPCs (Expansion [Exp]; black) and in differentiated adult CPCs (white and light gray), exposed or not to DAPT in the absence or presence of DAPT. Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs; † $p < 0.05$  as compared with differentiating unstimulated (None; white) CPCs in absence of DAPT ( $n = 3$ ).



**FIGURE 6 CARMEN Down-Regulation Promotes CPC Differentiation Into Cardiomyocytes**




**(A)** Expression of *CARMEN7*, *MIR-143*, *MIR-145*, *ELK1*, and *KLF4* transcripts in proliferating CPCs (Expansion [Expansion]; **black**) and in differentiated (Differentiation) adult CPCs without prior DLL1 stimulation and cultured in the absence of DAPT (None No DAPT). Cells were transfected with either scrambled GapmeRs (**white**), GapmeRs directed against all *CARMEN* isoforms (**light gray**), or GapmeRs directed specifically against *CARMEN7* (**dark gray**). Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs; # $p < 0.05$  as compared with differentiating CPCs (**white**) transfected with scrambled GapmeRs ( $n = 3$ ). **(B)** Expression of sarcomeric proteins (*MYH6*, *MYH7*, *MYH11*) in proliferating CPCs (Expansion; **black**) and in differentiated adult CPCs exposed or not to DLL1 in the absence or presence of DAPT. Cells were transfected with either scrambled GapmeRs (**white**), GapmeRs directed against all *CARMEN* isoforms (**light gray**), or GapmeRs directed specifically against *CARMEN7* (**dark gray**). Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs; # $p < 0.05$  as compared with differentiating CPCs (**white**) transfected with scrambled GapmeRs ( $n = 3$ ). **(C)** Analysis of SM-MHC,  $\alpha$ -ACTININ, TNNI, and MLC2V expression by immunostaining in differentiated CPCs exposed to DLL1 in the presence of DAPT, transfected with either scrambled GapmeRs (**white**), GapmeRs directed against all *CARMEN* isoforms (**light gray**), or GapmeRs directed specifically against *CARMEN7* (**dark gray**). Scale bar: 25  $\mu$ m. Quantification of the numbers of  $\alpha$ -ACTININ<sup>POS</sup>, TNNI<sup>POS</sup>, or MLC2V<sup>POS</sup> cardiomyocytes and sm-MHC<sup>POS</sup> smooth muscle cells. Data represent mean  $\pm$  SEM; \* $p < 0.05$  as compared with proliferating CPCs; # $p < 0.05$  as compared with differentiating CPCs (**white**) transfected with scrambled GapmeRs (minimum 1,500 cells in 20 different fields at a magnification of 40 $\times$  per quantification).

DLL1 and not cultured in DAPT-containing medium, *MYH6* and *MYH7* expression was not different than under controlled conditions. Nevertheless, *CARMEN* knockdown strikingly reinforce the cardiogenic program in committed cells. Large amounts of cardiomyocytes were detected in this case. Specifically, up to 60% of CPC clones adopted a cardiomyocyte fate. In particular, these cells demonstrated expression of the cardiac proteins  $\alpha$ -ACTININ, TNNT1, and myosin light chain 2 (MLC2V) (Figure 6C). Moreover, most of the cells are characterized by the presence of organized sarcomeres.

**GENE REGULATORY NETWORK CONTROLLING CPC DIFFERENTIATION.** In order to elucidate the transcriptional events associated with CPC differentiation, we profiled the transcriptome using RNA sequencing in differentiating fetal and adult CPCs under various conditions (Supplemental Table 2). We first performed a principal component analysis of all genes significantly modulated in either CPCs differentiating into cardiomyocytes or CPCs differentiating into smooth muscle cells (adjusted p value <0.05) (Figure 7A). Ninety-one percent of total variation can be attributed to the first 2 principal components. Strikingly, proliferating undifferentiated fetal and adult CPCs clustered together, consistent with the notion that these cells demonstrated a similar phenotype, and giving further support to previous analysis of surface marker expression (Figure 1) (31). In sharp contrast, differentiated fetal and adult CPCs clearly differed in this analysis, in accordance with their respective capacity to produce either cardiomyocytes or smooth muscle cells. However, adult CPCs exposed to DLL1 and induced to differentiate in the presence of DAPT, that is, producing cardiomyocytes, showed a shift along the PC1 and PC2 axes, and were similar to fetal CPC-derived cardiomyocytes. Hierarchical clustering confirmed that proliferating CPCs from fetal and adult hearts share an identical transcriptional signature (Figure 7B, 2nd and 3rd columns). Clustering analysis then demonstrated that genes activated in each situations giving rise to cardiomyocytes were down-regulated during differentiation into smooth muscle cells. Differentiation into cardiomyocytes was associated with relevant gene ontology (GO) terms and networks, such as cardiac development and morphogenesis, coupled to activation of specific cardiogenic pathways implicating important modulators of cardiogenesis, in particular NOTCH, WNT, BMP, FGF, and TGF $\beta$  (Clusters 3 and 4). Conversely, adult CPCs differentiating into smooth muscle cells expressed a transcriptional program associated with blood vessel development (Cluster 1).

In order to define a core transcriptional program controlling differentiation into cardiomyocytes, we first identified genes commonly modulated during fetal CPC differentiation and during differentiation of adult CPCs exposed to DLL1 and DAPT. Genes that were differentially expressed in adult CPCs differentiating into smooth muscle cells were subtracted from those that were common to both datasets (Figure 7C). We next determined GO category enrichment for up- and down-regulated genes. GO terms and networks associated with up-regulated genes (112 genes) were representative of cardiac differentiation and morphogenesis, and muscle contraction. On the contrary, negatively modulated genes (37 genes) were associated with smooth muscle cell differentiation, blood vessel morphogenesis, and angiogenesis. We also analyzed GO categories in up- and down-regulated genes, which were found uniquely modulated in adult CPCs differentiating into smooth muscle cells. Consistently, we found that up-regulated genes (569 genes) were associated with GO terms defining development of blood vessels. Interestingly, down-regulated genes (722 genes) were implicated primarily in neurogenesis.

To identify processes under control of NOTCH signaling, we next compared adult CPCs induced to differentiate following DLL1 exposure in the absence or presence of DAPT (Supplemental Figure 8A). GO term enrichment in genes that were up- and down-regulated exclusively in DLL1-sensitized CPCs cultured in DAPT-containing medium were determined. As expected, up-regulated genes (359 genes) were found to be implicated in cardiac development. Consistent with a control of smooth muscle cell differentiation by NOTCH-mediated expression of *MIR-143/145*, down-regulated genes (98 genes) were associated with blood vessel morphogenesis. Importantly, neurogenesis was also a prime target of NOTCH inhibition. A similar approach was used to determine processes under the control by the *CARMEN*. We compared differentiating adult CPCs following exposure to DLL1, transfected with either scrambled control GapmeRs or GapmeRs directed against all *CARMEN* isoforms in the absence of DAPT (Supplemental Figure 8B). Up-regulated genes (258 genes) were involved in cardiac muscle differentiation. This is in accordance with the transcriptional signature observed in the hierarchical clustering analysis (Figure 7B). Indeed, DLL1-activated adult CPCs treated with GapmeRs targeting *CARMEN* produced a signature similar to that of cardiogenic cells despite the fact that *CARMEN*-depleted adult CPCs produced smooth muscle cells. *CARMEN* down-regulation appeared to favor, therefore, the




Continued on the next page

emergence of a cardiogenic program, even if not sufficient to redirect CPCs into a cardiomyocyte fate.

Several important factors and transcriptional regulators were identified among the top modulated genes in cardiogenic CPCs. We confirmed their differential expression in various situations by quantitative RT-PCR (Supplemental Figure 8C). In particular, *HOPX*, a transcription factor implicated in

cardiomyocyte proliferation and differentiation, was markedly up-regulated (44). *Hopx* was recently shown to control cardiogenic commitment of cardiovascular progenitors in the developing mouse heart (45). Specifically, *Hopx* acts as a co-repressor in the BMP4 signaling pathway to modulate WNT and promote cardiogenesis. BMP2 and BMP4 expression were indeed induced in CPCs differentiating into cardiomyocytes. In addition, several WNT ligands

FIGURE 7 Continued



(C) Venn diagram of up- and down-regulated genes common or unique to fetal CPCs differentiating in cardiomyocytes (blue), adult CPCs differentiating into smooth muscle cells (green), and adult CPCs differentiating into cardiomyocytes following exposure to DLL1 and DAPT treatment (pink). Gene ontology terms and biological processes annotated by Gene Go are indicated for sets of genes common to cells differentiating into cardiomyocytes, and for set of genes unique to cells differentiating into smooth muscle cells. Abbreviations as in Figure 1.

were modulated, in particular WNT5A and WNT11, demonstrating a pattern of expression known to favor cardiogenic differentiation in cardiac progenitors (46). Key transcription factors playing crucial roles in cardiogenesis were found also up-regulated in adult CPCs giving rise to cardiomyocytes, such as *ISL1*, *IRX1*, *IRX2*, and *IRX4* (4,47). Finally, to identify potential factors regulating specification into cardiomyocytes, we performed a predictive analysis of upstream regulators using the gene set common to fetal and adult CPCs producing cardiomyocytes (Figure 7C, Supplemental Table 3). Among cytokines and growth factors that were predicted to regulate cardiogenic commitment, several factors were involved in cardiomyocyte differentiation and maintenance of cell identity, such as BMP4, FGF2, and CXCL12 (33,48,49), and as inducers of cell division in cardiac myocytes such as neuregulin (NRG1), oncostatin M (OSM), and interleukin (IL)13 (50,51).

## DISCUSSION

The rate of cardiomyocyte renewal in the adult mammalian heart is low, and not sufficient to replenish the heart with newly formed myocytes following injury (2). The reasons for this relative incapacity of the heart to induce effective regeneration are still obscure. Many laboratories have identified various kinds of CPCs, which demonstrate ability to generate cardiomyocytes in vitro (3,4). However, these cells usually have a poor capacity to produce a functional myocardium in vivo. In the present study, we have isolated a subpopulation of multipotent clonogenic CPCs from human atrial appendages. These cells demonstrate a unique pattern of surface marker expression. Indeed, CPC clones express uniformly CD73, CD90, and CD105, which characterize these cells as multipotent mesenchymal stromal cells. In addition, the expression of CD146 suggest a



possible pericyte origin (37). By contrast, clones express neither NG2 nor PDGFR $\alpha$  (CD140a). Cardiac-resident mesenchymal stromal cells that occupy a perivascular adventitial niche have been described (52). However, these cells express PDFGR $\alpha$ , contrary to the adult CPCs described in our study. Moreover, this also distinguishes them from pericytes recently isolated from human ventricles (53). Finally, these cells do not express CD117, CD31, CD34, CD45, and CXCR4. More importantly, human adult CPCs coexpressed *NKX2.5*, *GATA4*, and *MEF2C*. Furthermore, cardiac transcription factors such as *TBX5* and *HAND2* are up-regulated in CPCs differentiating into cardiomyocytes. In the normal heart, 25% of resident cardiac non-myocyte cells were found to be positive for *GATA4*, *MEF2C*, and *TBX5* (54). Interestingly, forced expression of cardiac transcription factors, in combination with activators of Wnt and JAK/STAT signaling, was able to reprogram cardiac non-myocyte cells into cardiac progenitors, and finally, relatively mature cardiomyocytes (55-57). Nevertheless, intrinsic pre-specification in vivo is not sufficient, and cardiogenic non-myocyte cells do not contribute new cardiomyocytes post-myocardial infarction (54). The reason why pre-specified cells do not spontaneously complete cardiogenic differentiation is currently unknown. However, our results provide a possible scenario. It appears that adult CPCs preferentially produce smooth muscle cells over cardiomyocytes. This is in line with observations suggesting that increased perfusion more than de novo cardiogenesis produces beneficial effects in cell therapy for heart disease. Moreover, paracrine factors released from the transferred cells are thought to stimulate angiogenesis and promote repair in the injured heart (58). Therefore, reprogramming toward the cardiomyocyte fate might be needed in order to reveal the full potential of adult CPCs in vivo. Sequential activation and inhibition of NOTCH signaling is sufficient to redirect CPCs from a default smooth muscle commitment to a differentiation into cardiomyocytes. Importantly, results using clonal CPC populations formally demonstrate their capacity for development in either of 2, apparently mutually exclusive, lineages. Prior activation of NOTCH signaling via exposure to NOTCH ligand is a prerequisite for revealing the dormant capacity of CPCs to produce cardiomyocytes. The NOTCH pathway has been shown to promote CPC commitment and expansion in the developing and postnatal hearts (9,17,18). Accordingly, we show that key cardiac transcription factors such as *NKX2.5*, *GATA4*, *MEF2C*, and *TBX5* are up-regulated in human adult CPCs exposed to DLL1, and proliferation is stimulated.

This is also reminiscent of a situation observed in the heart of transgenic mice overexpressing Jagged1, in which the number of NKX2.5-positive CPCs is significantly increased (14). Of note, NOTCH also stimulates proliferation in immature cardiomyocytes (39,40). Moreover, in embryonic stem cells and in undifferentiated precursors, NOTCH is known to inhibit cardiogenesis and maturation (10,15). Our observation supports, therefore, the notion that NOTCH activates a cardiogenic program in adult CPCs while preventing terminal differentiation to promote expansion. In addition, one target of NOTCH signaling in adult CPCs is the locus encoding *MIR-143/145*, 2 miRNAs that are known to promote smooth muscle differentiation (20,21). Therefore, NOTCH activates simultaneously a smooth muscle cell program. As a consequence, NOTCH inhibition is, on one hand, mandatory for alleviating the inhibitory action of NOTCH on cardiogenesis and, on the other hand, for blocking the activation of the smooth muscle program.

In the *MIR-143/145* locus, NOTCH activates a proximal enhancer element that is associated with different isoforms of an enhancer-associated lncRNA. We recently named this enhancer-associated lncRNA *CARMEN*, and demonstrated its importance as a regulator of cardiac differentiation (20,32). Enhancers are cis-regulatory genomic elements that integrate chromatin state transitions to elicit appropriate transcriptional and cellular responses. In recent years, it has become evident that pervasive transcription occurs at active enhancer sequences during different cellular contexts, in particular during specification and differentiation (29,30). Interestingly, the vast majority of differentially modulated heart-enriched lncRNAs following myocardial infarction were derived from active enhancers (24,27). Enhancer-associated lncRNAs activate target gene expression primarily via cis mechanisms involving chromatin looping between the enhancer sequences and their target genes within neighboring or distal domains (30,43). Several studies, including ours, demonstrated that degradation of particular enhancer-associated lncRNAs is sufficient to reduce expression of their target coding genes (24,27). In the present study, we show that specification toward the smooth muscle cell fate in adult CPCs depends on *CARMEN* expression. More specifically, among the different *CARMEN* isoforms that are produced upon enhancer activation, *CARMEN7* is of crucial importance. A positive correlation exists in adult CPCs between *CARMEN7* and *MIR-143/145* expression. Moreover, *CARMEN7* is down-regulated following sequential NOTCH



activation and inhibition resulting in the reactivation of the cardiogenic program. Accordingly, *CARMEN7* knockdown results in *MIR-143/145* down-regulation and blocks differentiation of adult CPCs into smooth muscle cells. Altogether, these data are consistent with a *cis* regulation of *MIR-143/145* expression by *CARMEN* via *CARMEN7* production in adult CPCs. Targets of *MIR-143/145* that regulate smooth muscle cell proliferation and differentiation have been identified (21). In particular, the pluripotency factor KLF4, a *MIR-145* target, inhibits terminal differentiation and promotes expansion of smooth muscle cells following injury. Furthermore, the *MIR-143* target ELK-1 is known as a competitive inhibitor of MYOCARDIN. Finally, other *MIR-143/145* targets can be implicated in maintaining smooth muscle identity. For instance, *MIR-145* has been recently shown to regulate TGF $\beta$  receptor II expression in smooth muscle cells (59). TGF $\beta$  is known to drive smooth muscle differentiation (60).

The situation observed in adult CPCs is in contrast to what is seen in fetal CPCs, in which *CARMEN7* is not significantly expressed. In fetal CPCs spontaneously differentiating into cardiomyocytes, *MIR-143/145* expression is inversely correlated with expression of other *CARMEN* isoforms, which are indispensable for the induction of cardiogenesis (32). It is also important to note that none of these *CARMEN* isoforms represent the precursor of the 2 miRNAs. Indeed, because a negative correlation exists in differentiating fetal CPCs between *CARMEN* and *MIR-143/145* expression, *CARMEN* induction is associated to *MIR-143/145* down-regulation, and *CARMEN* depletion induces *MIR-143/145* expression. Moreover, *CARMEN* boundaries have been well defined by analysis of promoter-specific histone modification and polyA signal frequency (61,62). Isoforms of *CARMEN*, and in particular *CARMEN7*, terminate at a position situated upstream of the 2 miRNAs. Finally, *CARMEN* regulates cardiogenesis independently of *MIR-143/145* expression in fetal CPCs (32). Altogether, this suggests also that *CARMEN* transcripts other than *CARMEN7* exert *trans* regulatory function to initiate the cardiogenic program. Indeed, many characterized lncRNAs operate in *trans* as decoys or recruiters for transcription factors and chromatin-remodeling complexes. lncRNAs act efficiently at remote locations in the genome via their particular affinity with RNA-binding proteins such as components of the Trithorax and Polycomb complexes to activate or silence specific expression programs (63).

Gene clustering analysis supports the view that smooth muscle cell specification in adult CPCs prevents expression of the cardiogenic program. GO

analysis demonstrates that cardiac differentiation is not induced in adult CPCs not exposed to DLL1 or in NOTCH-activated cells without following inhibition. In these instances, *MIR-143/145* expression is activated and smooth muscle cells are produced. Interestingly, *CARMEN* down-regulation alone is not sufficient to implement cardiomyocyte production. Strikingly, however, adult CPCs exposed to DLL1 and transfected with anti-*CARMEN* GapmeRs are characterized by a gene expression pattern similar to that observed in adult CPCs differentiating into cardiomyocytes. Therefore, cardiogenesis is initiated by concomitant activation of the NOTCH pathway and *CARMEN* down-regulation but is not productively efficient. This observation emphasizes the strength of NOTCH-mediated inhibition on cardiac differentiation and maturation. This also suggests that NOTCH blockade exerts pro-cardiogenic effects beyond *CARMEN* down-regulation and subsequent modulation of *MIR-143/145* expression. Our transcriptional data indicate that neurogenesis might need to be inhibited before the cardiogenic program can be initiated. Along this line, a binary cell fate decision between the cardiac mesoderm and the neuroectoderm has been shown to be controlled by NOTCH in embryonic stem cells (15). Remarkably, under conditions of NOTCH and *CARMEN* inhibition, up to 60% of differentiated cells are terminally differentiated cardiomyocytes, and practically none are smooth muscle cells. Altogether, these data suggest that NOTCH and *CARMEN* cooperate to control specification into the cardiomyocyte and smooth muscle lineages. Within this gene regulatory network controlling CPC differentiation, *MIR-143/145* down-regulation is a mandatory step that permits cardiomyocyte specification. The visual abstract proposes a schematic of the molecular pathways implicated in the control of fate in human adult CPCs. Interestingly, HOPX is highly induced in CPCs specified to the cardiac lineage. This transcriptional repressor has been recently shown to be expressed in cardiogenic cell intermediates in the developing mouse heart (45). Hopx is necessary for BMP4-mediated repression of Wnt signaling. Importantly, Hopx-positive cells give rise exclusively to cardiomyocytes. It is therefore possible that reactivation of this developmental pathway in adult CPCs forces the cells to adopt a cardiomyocyte fate.

Appropriately specified CPCs produce functional cardiomyocytes in vivo and in vitro. Cardiomyocytes demonstrate spontaneous and triggered calcium signals. In particular, rapid synchronized calcium transients are readily observable in CPC-derived cardiomyocytes following electrical stimulation, indicating that cardiomyocytes develop electrical

competence similar to that of mature cardiomyocytes. Furthermore, CPCs differentiate into cardiomyocytes in vivo. These cells engraft in the mouse post-natal heart and form structures that appear functionally integrated in the host myocardium. These findings indicate that the atrial appendage-derived CPCs described in the present study could represent a valuable source of precursors in cell replacement therapy for heart disease. Provided that NOTCH is inhibited following CPC injection into the damaged myocardium, cardiomyocytes could be produced at the site of injury. In this regard, although unspecific  $\gamma$ -secretase inhibitors can produce toxicity in vivo, in particular in the gut, this difficulty can be overcome using selective blockers of NOTCH receptor paralogs (41). We have indeed tested this possibility, and demonstrated that NRR1 antibodies can substitute for DAPT during production of CPC-derived cardiomyocytes. Finally, we recently demonstrated that *CARMEN* is induced in human cardiac pathologies and in mouse models of cardiac disease (32). In this context, it would be interesting to evaluate whether manipulation of endogenous cardiogenic mesenchymal precursors in vivo via modulation of the NOTCH-*CARMEN-MIR-143/145* axis is able to favor cardiomyocyte renewal in the damaged heart, and promotes true heart regeneration.

## CONCLUSIONS AND LIMITATIONS

With the advent of reprogramming technologies, a novel approach to regeneration has emerged. In the context of our study, reprogramming particularly pertains to the controlled differentiation of CPCs into specific cardiac cells. Our study demonstrates that the subclass of lncRNAs that are associated to enhancer sequences can be manipulated to specify human CPCs into particular fates. Moreover, our findings suggest that the different lncRNA isoforms, produced by a single locus, regulate distinct gene programs, producing therefore diverse cellular responses. lncRNA isoform-specific effects certainly warrant further investigation. Altogether, these findings open new perspectives for the treatment of heart disease, and more specifically in cell replacement therapies. Several points should be however considered. *MIR-143/145* are most likely not the sole targets of *CARMEN* transcripts. Within the frame of our study, we have not investigated *trans* mechanisms of actions. lncRNAs are known to regulate gene transcription at remote locations in the genome, different from their own site of transcription.

In addition, lncRNAs can translocate into the cytoplasm whether they can associate with specific modulators of cell identity and behavior. Furthermore, NOTCH signaling exerts also a variety of actions that should be investigated. This integrated network implicating a signaling pathway, lncRNAs and miRNAs provide nevertheless a fascinating example of the complexity of the molecular mechanisms that regulate cell plasticity in organs such as the heart.

**ACKNOWLEDGMENTS** The authors are grateful to Andrée Porret for her technical assistance. The authors thank Sandra Calderon and Sylvain Pradervand, Genomic Technologies Facility, University of Lausanne, Switzerland, for helping with transcriptomic data analysis, and Yannick Kremp, Cellular Imaging Facility, University of Lausanne, Switzerland, for providing expertise in confocal microscopy. The authors also thank Dr. Michael B. Elowitz, California Institute of Technology, Pasadena, California, for making the hN1 reporter cell line available to them. The NRR1 antibodies were a kind gift from Christian W. Siebel, Genentech, South San Francisco, California.

**REPRINT REQUESTS AND CORRESPONDENCE:** Dr. Thierry Pedrazzini, Experimental Cardiology Unit, Department of Medicine, University of Lausanne Medical School, CH-1011 Lausanne, Switzerland. E-mail: [thierry.pedrazzini@chuv.ch](mailto:thierry.pedrazzini@chuv.ch).

## PERSPECTIVES

**COMPETENCY IN MEDICAL KNOWLEDGE:** Cellular replacement therapies for heart disease represent promising therapeutic approaches. However, even if improvement in cardiac function is sometime observed, the generation of a new myocardium in the human heart has never been demonstrated. This has been attributed to a relative incapacity of cardiac precursor cells to produce cardiomyocytes. Long noncoding (lnc) RNAs are emerging as master regulator of cell specification and differentiation. Within this context, these molecules play crucial roles in generating cell-specific programs, which regulate cell identity. These properties can be utilized to program precursor cells to adopt a cardiomyocyte fate.

**TRANSLATIONAL OUTLOOK:** Future research should take advantage of the high potential of lncRNAs to regulate cell-specific patterns of gene expression to control the fate of precursor cells used in cell therapies and improved cardiomyocyte production in the damaged heart.

## REFERENCES

1. Towbin JA, Bowles NE. The failing heart. *Nature* 2002;415:227-33.
2. Garbern JC, Lee RT. Cardiac stem cell therapy and the promise of heart regeneration. *Cell Stem Cell* 2013;12:689-98.
3. van Berlo JH, Molkenkin JD. An emerging consensus on cardiac regeneration. *Nat Med* 2014;20:1386-93.
4. Sahara M, Santoro F, Chien KR. Programming and reprogramming a human heart cell. *EMBO J* 2015;34:710-38.
5. Nemir M, Pedrazzini T. Functional role of Notch signaling in the developing and postnatal heart. *J Mol Cell Cardiol* 2008;45:495-504.
6. de la Pompa JL, Epstein JA. Coordinating tissue interactions: Notch signaling in cardiac development and disease. *Dev Cell* 2012;22:244-54.
7. Kopan R. Notch signaling. *Cold Spring Harb Perspect Biol* 2012;4:a011213.
8. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. *J Cell Physiol* 2003;194:237-55.
9. Urbanek K, Cabral-da-Silva MC, Ide-Iwata N, et al. Inhibition of notch1-dependent cardiomyogenesis leads to a dilated myopathy in the neonatal heart. *Circ Res* 2010;107:429-41.
10. Croquelois A, Domenighetti AA, Nemir M, et al. Control of the adaptive response of the heart to stress via the Notch1 receptor pathway. *J Exp Med* 2008;205:3173-85.
11. Gude NA, Emmanuel G, Wu W, et al. Activation of Notch-mediated protective signaling in the myocardium. *Circ Res* 2008;102:1025-35.
12. Kratsios P, Catela C, Salimova E, et al. Distinct roles for cell-autonomous Notch signaling in cardiomyocytes of the embryonic and adult heart. *Circ Res* 2010;106:559-72.
13. Russell JL, Goetsch SC, Gaiano NR, Hill JA, Olson EN, Schneider JW. A dynamic notch injury response activates epicardium and contributes to fibrosis repair. *Circ Res* 2011;108:51-9.
14. Nemir M, Metrich M, Plaisance I, et al. The Notch pathway controls fibrotic and regenerative repair in the adult heart. *Eur Heart J* 2014;35:2174-85.
15. Nemir M, Croquelois A, Pedrazzini T, Radtke F. Induction of cardiogenesis in embryonic stem cells via downregulation of Notch1 signaling. *Circ Res* 2006;98:1471-8.
16. Liu Y, Li P, Liu K, et al. Timely inhibition of Notch signaling by DAPT promotes cardiac differentiation of murine pluripotent stem cells. *PLoS One* 2014;9:e109588.
17. Boni A, Urbanek K, Nascimbene A, et al. Notch1 regulates the fate of cardiac progenitor cells. *Proc Natl Acad Sci U S A* 2008;105:15529-34.
18. Gude N, Joyo E, Toko H, et al. Notch activation enhances lineage commitment and protective signaling in cardiac progenitor cells. *Basic Res Cardiol* 2015;110:488.
19. Chen L, Ashraf M, Wang Y, et al. The role of notch 1 activation in cardiosphere derived cell differentiation. *Stem Cells Dev* 2012;21:2122-9.
20. Boucher JM, Peterson SM, Urs S, Zhang C, Liaw L. The miR-143/145 cluster is a novel transcriptional target of Jagged-1/Notch signaling in vascular smooth muscle cells. *J Biol Chem* 2011;286:28312-21.
21. Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. *Nature* 2009;460:705-10.
22. Guttman M, Donaghey J, Carey BW, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. *Nature* 2011;477:295-300.
23. Flynn RA, Chang HY. Long noncoding RNAs in cell-fate programming and reprogramming. *Cell Stem Cell* 2014;14:752-61.
24. Ounzain S, Pezzuto I, Micheletti R, et al. Functional importance of cardiac enhancer-associated noncoding RNAs in heart development and disease. *J Mol Cell Cardiol* 2014;76C:55-70.
25. Klattenhoff CA, Scheuermann JC, Surface LE, et al. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. *Cell* 2013;152:570-83.
26. Grote P, Wittler L, Hendrix D, et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. *Dev Cell* 2013;24:206-14.
27. Ounzain S, Micheletti R, Beckmann T, et al. Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. *Eur Heart J* 2015;36:353-68.
28. Boon RA, Jae N, Holdt L, Dimmeler S. Long noncoding RNAs: from clinical genetics to therapeutic targets? *J Am Coll Cardiol* 2016;67:1214-26.
29. Orom UA, Shiekhattar R. Long noncoding RNAs usher in a new era in the biology of enhancers. *Cell* 2013;154:1190-3.
30. Ounzain S, Pedrazzini T. The promise of enhancer-associated long noncoding RNAs in cardiac regeneration. *Trends Cardiovasc Med* 2015;25:592-602.
31. Gonzales C, Ullrich ND, Gerber S, Berthonneche C, Niggli E, Pedrazzini T. Isolation of cardiovascular precursor cells from the human fetal heart. *Tissue Eng Part A* 2012;18:198-207.
32. Ounzain S, Micheletti R, Arnan C, et al. CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. *J Mol Cell Cardiol* 2015;89:98-112.
33. Rosenblatt-Velin N, Lepore MG, Cartoni C, Beermann F, Pedrazzini T. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. *J Clin Invest* 2005;115:1724-33.
34. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 2010;26:139-40.
35. Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol* 2014;15:R29.
36. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;43:e47.
37. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. *Stem Cells* 2008;26:2287-99.
38. Sprinzak D, Lakhnani P, Lebon L, et al. Cis-interactions between Notch and Delta generate mutually exclusive signalling states. *Nature* 2010;465:86-90.
39. Campa VM, Gutierrez-Lanza R, Cerignoli F, et al. Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. *J Cell Biol* 2008;183:129-41.
40. Collesi C, Zentilin L, Sinagra G, Giacca M. Notch1 signaling stimulates proliferation of immature cardiomyocytes. *J Cell Biol* 2008;183:117-28.
41. Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. *Nature* 2010;464:1052-7.
42. Lan F, Lee AS, Liang P, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. *Cell Stem Cell* 2013;12:101-13.
43. Li W, Notani D, Rosenfeld MG. Enhancers as non-coding RNA transcription units: recent insights and future perspectives. *Nat Rev Genet* 2016;17:207-23.
44. Kook H, Epstein JA. Hopping to the beat. Hop regulation of cardiac gene expression. *Trends Cardiovasc Med* 2003;13:261-4.
45. Jain R, Li D, Gupta M, et al. Integration of Bmp and Wnt signaling by Hopx specifies commitment of cardiomyoblasts. *Science* 2015;348:aaa6071.
46. Gessert S, Kuhl M. The multiple phases and faces of wnt signaling during cardiac differentiation and development. *Circ Res* 2010;107:186-99.
47. Kim KH, Rosen A, Bruneau BG, Hui CC, Backx PH. Iroquois homeodomain transcription factors in heart development and function. *Circ Res* 2012;110:1513-24.
48. Cagavi E, Bartulos O, Suh CY, et al. Functional cardiomyocytes derived from Isl1 cardiac progenitors via Bmp4 stimulation. *PLoS One* 2014;9:e110752.
49. Malliaras K, Ibrahim A, Tseliou E, et al. Stimulation of endogenous cardioblasts by exogenous cell therapy after myocardial infarction. *EMBO Mol Med* 2014;6:760-77.
50. Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte

proliferation and repair of heart injury. *Cell* 2009;138:257-70.

51. O'Meara CC, Wamstad JA, Gladstone RA, et al. Transcriptional reversion of cardiac myocyte fate during Mammalian cardiac regeneration. *Circ Res* 2015;116:804-15.

52. Chong JJ, Chandrakanthan V, Xaymardan M, et al. Adult cardiac-resident MSC-like stem cells with a proepicardial origin. *Cell Stem Cell* 2011;9:527-40.

53. Chen WC, Baily JE, Corselli M, et al. Human myocardial pericytes: multipotent mesodermal precursors exhibiting cardiac specificity. *Stem Cells* 2015;33:557-73.

54. Furtado MB, Costa MW, Pranoto EA, et al. Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. *Circ Res* 2014;114:1422-34.

55. Qian L, Berry EC, Fu JD, Ieda M, Srivastava D. Reprogramming of mouse fibroblasts into

cardiomyocyte-like cells in vitro. *Nat Protoc* 2013;8:1204-15.

56. Song K, Nam YJ, Luo X, et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. *Nature* 2012;485:599-604.

57. Lalit PA, Salick MR, Nelson DO, et al. Lineage reprogramming of fibroblasts into proliferative induced cardiac progenitor cells by defined factors. *Cell Stem Cell* 2016;18:354-67.

58. Hodgkinson CP, Bareja A, Gomez JA, Dzau VJ. Emerging concepts in paracrine mechanisms in regenerative cardiovascular medicine and biology. *Circ Res* 2016;118:95-107.

59. Zhao N, Koenig SN, Trask AJ, et al. MicroRNA miR145 regulates TGFBR2 expression and matrix synthesis in vascular smooth muscle cells. *Circ Res* 2015;116:23-34.

60. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. *Physiol Rev* 2004;84:767-801.

61. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res* 2012;22:1775-89.


62. Zhang H, Hu J, Recce M, Tian B. PolyA\_DB: a database for mammalian mRNA polyadenylation. *Nucleic Acids Res* 2005;33:D116-20.

63. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. *Cell* 2013;152:1298-307.

---

**KEY WORDS** cardiac precursor cells, differentiation, heart disease, lncRNAs, miRNAs, NOTCH

---

 **APPENDIX** For an expanded methods section and supplemental figures, tables, and videos, please see the online version of this article.